
Opinion|Videos|June 17, 2024
Adverse Effect Management and the Role of Immunotherapy in NMIBC
Experts on bladder cancer discusses strategies to minimize adverse effects and the role of immunotherapy in BCG-unresponsive NMIBC treatment paradigms.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Integration of doublet and triplet therapy in metastatic prostate cancer
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5







